Alpha 2.0
Login Register
» Authors » Hugo Mananet

Hugo Mananet

Explore the profile of Hugo Mananet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 54
Followers 0
Related Specialties
Oncology
Molecular Biology
General Medicine
Top 10 Co-Authors
Romain Boidot
Caroline Truntzer
Valentin Derangere
Francois Ghiringhelli
Laurent Arnould
Julie Lecuelle
Juliette Albuisson
Elise Ballot
Sandy Chevrier
Jean-David Fumet
Published In
Cancers (Basel)
Breast Cancer Res
Nat Med
Int J Mol Med
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer
Peroz M, Mananet H, Roussot N, Kaderbhai C, Derangere V, Truntzer C, et al.
Cancers (Basel) . 2024 Sep; 16(17). PMID: 39272973
Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in...
2.
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC
Roussot N, Thibaudin M, Fumet J, Daumoine S, Hampe L, Rebe C, et al.
Front Immunol . 2024 Aug; 15:1437961. PMID: 39170614
A patient with a PD-L1-negative, TMB-low, co-mutated metastatic non-small cell lung cancer (NSCLC) experienced a multisite radiological progression at 3 months after initiation of chemoimmunotherapy as first-line treatment for metastatic...
3.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Thibaudin M, Fumet J, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, et al.
Nat Med . 2023 Aug; 29(8):2087-2098. PMID: 37563240
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm,...
4.
Novel Association of the NOTCH Pathway Regulator MIB1 Gene With the Development of Bicuspid Aortic Valve
Tessler I, Albuisson J, Pineiro-Sabaris R, Verstraeten A, Kamber Kaya H, Siguero-Alvarez M, et al.
JAMA Cardiol . 2023 Jul; 8(8):721-731. PMID: 37405741
Importance: Nonsyndromic bicuspid aortic valve (nsBAV) is the most common congenital heart valve malformation. BAV has a heritable component, yet only a few causative genes have been identified; understanding BAV...
5.
Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, et al.
Int J Mol Sci . 2023 Apr; 24(8). PMID: 37108755
Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated...
6.
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, et al.
Breast Cancer Res . 2022 Nov; 24(1):80. PMID: 36401316
Purpose: The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative...
7.
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, et al.
NPJ Breast Cancer . 2022 Mar; 8(1):28. PMID: 35246547
Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease course. The real benefit of these treatments is uncertain at advanced stages of the disease and in...
8.
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use
Chevrier S, Brasselet A, Carnet M, Chevriaux A, Gibeaud A, Jourdain M, et al.
Int J Mol Med . 2022 Mar; 49(5). PMID: 35244186
Molecular testing is extremely important in cancer care, starting as early as at diagnosis. In order to address the challenge of providing reliable results within the timeframe adapted to patient...
9.
TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer
Lecuelle J, Boidot R, Mananet H, Derangere V, Albuisson J, Goussot V, et al.
Cancers (Basel) . 2021 Sep; 13(17). PMID: 34503204
Purpose: Immune infiltration is a prognostic factor in high-grade serous ovarian carcinoma (HGSC) but immunotherapy efficacy is disappointing. Genomic instability is now used to guide the therapeutic value of PARP...
10.
An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R
Cancers (Basel) . 2021 Jul; 13(13). PMID: 34206535
PARP inhibitors yield interesting outcomes for patients with ovarian tumors harboring or mutation, but also with other tumors with homologous repair (HR) deficiency. About 40% of variants are variants of...